This clinical research study will help researchers answer questions about the study drug, which is called mavorixafor.
Mavorixafor is an investigational oral medication taken as a capsule.
This is a Phase 1b study, which means researchers want to know what dosage of mavorixafor, (the study drug) is safe.
The study drug will be taken in combination with ibrutinib, an FDA-approved treatment for WM.
The study is being conducted as part of a collaboration with The Leukemia & Lymphoma Society to help advance the development of mavorixafor for the treatment of WM.